<DOC>
	<DOCNO>NCT02007252</DOCNO>
	<brief_summary>This study design assess safety , tolerability efficacy ACZ885 aneurysmal growth rate subject abdominal aortic aneurysm ( AAA ) . The purpose study provide data enable decision regard development ACZ885 subject abdominal aortic aneurysm . The design study address primary objective evaluate change aneurysmal size subject AAA result treatment ACZ885 .</brief_summary>
	<brief_title>ACZ885 Treatment Abdominal Aortic Aneurysm</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Abdominal</mesh_term>
	<criteria>Key 1 . Male female subject age ≥45 year age 2 . Infrarenal abdominal aortic aneurysm maximum diameter : men ≥40mm ≤50mm ; woman ≥38mm ≤48mm . 3 . On stable medical regimen least 2 week prior dose , per investigator assessment . 4 . Have evaluable ultrasound image screen quantitative determination AAA size , per image core lab assessment . 5 . At screening , vital sign within follow range : ( ) oral body temperature 35.037.5°C ; ( b ) systolic blood pressure , 90170 mm Hg ; ( c ) diastolic blood pressure , 50100 mm Hg ; ( ) pulse rate , 40 100 bpm . Key 1 . Use investigational drug time enrollment , within 5 halflives enrollment . 2 . Known diabetes medical history , HbA1c ≥6.5 % screening , active diabetic medical regimen . 3 . History malignancy organ system localize basal cell carcinoma skin , treat untreated , within past 5 year . 4 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose 30day follow period study . 5 . Donation loss 400 ml blood within eight ( 8 ) week prior initial dosing , longer required local regulation . 6 . Subjects follow medication : ( ) Chronic systemic steroid treatment systemic immunosuppression ; ( b ) Any biologic drug target immune system , along history previous use drug . 7 . Presence nonhealing wound infection , include active urinary tract infection , recent process require significant tissue heal per investigator assessment . 8 . Significant illness resolve within four ( 4 ) week prior initial dose life expectancy le 2 year . 9 . Any following concomitant hepatic renal condition disease : ( ) Nephrotic syndrome , eGFR less 30 mL/min/1.73 m2 per CRCL formula ; ( b ) Prior organ transplant require immunosuppressive therapy ; ( c ) Known active recurrent hepatic disorder . 10 . Previous infrarenal aortic surgery 11 . Planned major surgery 12 . Known aortic dissection 13 . Subjects eligible AAA diameter , know slow growth ( &lt; 2mm/year ) know stable AAA size prior one year surveillance per investigator assessment . 14 . Subjects exhibit sign clinically concern unstable acceleration AAA size growth rate time enrollment per investigator assessment . 15 . Known suspect inherited connective tissue disorder ( e.g. , Marfan Vascular Ehlers Danlos syndrome ) . 16 . Recently unstable clinically significant cardiac disease within 3 month screen , include limited , unstable angina , acute myocardial infarction , congestive heart failure ( NYHA class IV ) . 17 . Uncontrolled refractory hypertension per Investigator determination . 18 . Live vaccination within 3 month prior randomization , live vaccination plan study . 19 . History untreated tuberculosis infection evidence active tuberculosis ( TB ) infection . 20 . History multiple recur allergy allergy investigational compound/compound class use study . 21 . History immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result . 22 . A positive Hepatitis B surface antigen Hepatitis C test result whether screen historically . 23 . For USA sit utilizing CT angiogram , subject history previous reaction contrast agent , know sensitivity iodine know allergy ( e.g , shellfish allergy ) , hypersensitivity contrast agent . 24 . Underlying immune disorder , autoimmunity immunodeficiency . 25 . History drug alcohol abuse within 12 month prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Abdominal Aortic Aneurysm</keyword>
	<keyword>AAA</keyword>
	<keyword>IL-1b</keyword>
	<keyword>Abdominal ultrasound</keyword>
</DOC>